Principal Financial Group Inc. Raises Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Principal Financial Group Inc. lifted its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 1,058.1% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 411,414 shares of the biotechnology company’s stock after purchasing an additional 375,890 shares during the period. Principal Financial Group Inc.’s holdings in BioCryst Pharmaceuticals were worth $3,127,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Exome Asset Management LLC bought a new position in shares of BioCryst Pharmaceuticals in the third quarter worth about $1,493,000. Franklin Resources Inc. raised its stake in BioCryst Pharmaceuticals by 177.8% during the 3rd quarter. Franklin Resources Inc. now owns 263,748 shares of the biotechnology company’s stock worth $1,968,000 after acquiring an additional 168,790 shares during the period. Sanctuary Advisors LLC lifted its holdings in BioCryst Pharmaceuticals by 78.3% during the third quarter. Sanctuary Advisors LLC now owns 47,389 shares of the biotechnology company’s stock valued at $360,000 after purchasing an additional 20,818 shares in the last quarter. SkyView Investment Advisors LLC boosted its position in shares of BioCryst Pharmaceuticals by 30.0% in the third quarter. SkyView Investment Advisors LLC now owns 13,000 shares of the biotechnology company’s stock worth $99,000 after purchasing an additional 3,000 shares during the period. Finally, Geode Capital Management LLC increased its stake in shares of BioCryst Pharmaceuticals by 2.7% in the third quarter. Geode Capital Management LLC now owns 4,837,985 shares of the biotechnology company’s stock worth $36,776,000 after purchasing an additional 127,708 shares in the last quarter. 85.88% of the stock is owned by institutional investors.

BioCryst Pharmaceuticals Stock Down 1.7 %

BCRX opened at $7.70 on Friday. The company has a market capitalization of $1.59 billion, a PE ratio of -12.62 and a beta of 1.76. BioCryst Pharmaceuticals, Inc. has a 52 week low of $4.03 and a 52 week high of $8.88. The firm has a 50-day simple moving average of $7.61 and a two-hundred day simple moving average of $7.51.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings data on Monday, November 4th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.07). The firm had revenue of $117.10 million during the quarter, compared to the consensus estimate of $113.99 million. The business’s revenue was up 35.1% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.19) EPS. As a group, sell-side analysts expect that BioCryst Pharmaceuticals, Inc. will post -0.38 earnings per share for the current year.

Wall Street Analysts Forecast Growth

BCRX has been the topic of a number of analyst reports. Needham & Company LLC restated a “buy” rating and set a $14.00 target price on shares of BioCryst Pharmaceuticals in a research note on Tuesday, November 5th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $10.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Tuesday, November 5th. Finally, Barclays lifted their target price on BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the company an “equal weight” rating in a research note on Tuesday, November 5th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $15.60.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.